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Abstract. Background: To present actual data to es-
timate prevalence, incidence and mortality of known
type 2 diabetes mellitus in all age categories in The
Netherlands. Methods: Prospective population-based
study between 1998 and 2000 in The Netherlands.
Baseline population of 155,774 patients, registered
with 61 general practitioners participating in the
Zwolle Outpatient Diabetes project Integrating
Available Care (ZODIAC)-study. Results: Age- and
sex-adjusted prevalence of type 2 diabetes was 2.2%
at baseline and 2.9% after 2 years of follow-up; for
women and men it was 3.1 and 2.7% at follow-up,
respectively. Patients aged >70 years account for
almost 50% of all type 2 diabetes patients. Age- and
sex-adjusted mean annual incidence per 10,000 over
3 years was 22.7 overall; for women 23.1 and for men
22.2. Incidence – even though high – decreases after
the age of 70 years. The mortality rate was 47.9/1000
and standardised mortality ratio 1.40. Based on these
results, the estimated total number of subjects known
with type 2 diabetes was 466,000 for The Netherlands
in 2000; the number of patients with newly diagnosed
diabetes 36,000. Conclusions: Prevalence and inci-
dence rates exceed all estimates regarding known type
2 diabetes for The Netherlands. Elderly patients, aged
70 years and over, account for 50% of the type 2
diabetic population. These results are important for
health-care planning.
Key words: Age groups, Diabetes mellitus, Incidence, Mortality, Prevalence, Prospective study, Type 2
Abbreviations: ADA ¼ American Diabetes Association; CI ¼ conﬁdence interval; GP ¼ general practitioner;
SD ¼ standard deviation; SMR ¼ standardised mortality ratio; SPSS ¼ Statistical Package for Social Sciences;
UK ¼ United Kingdom; US ¼ United States of America; WHO ¼World Health Organisation; ZODIAC ¼
Zwolle Outpatient Diabetes project Integrating Available Care
Introduction
Type 2 diabetes mellitus is a chronic disease, leading
to considerable morbidity and premature mortality
[1, 2]. The prevalence is high, especially in the elderly,
and increasing [3]. Accurate information about the
prevalence of known type 2 diabetes and the number
of newly diagnosed cases in the community is essen-
tial for health-care planning. In The Netherlands,
estimates on current and future incidence, prevalence
and mortality are available, based on various studies
[4–9]. However, the data used originate from 1993 or
earlier, estimates on incidence and prevalence vary
considerably [8], and few studies describe older age
categories in detail. This variation in estimates on
current and future incidence and prevalence may be
explained by the diﬀerences in models used for future
projections, by the year the data used for these pro-
jections originate from, and also by diﬀerences in the
design of studies supplying original data for these
estimates. Between studies with a diﬀerent study de-
sign – using oral glucose tolerance tests or based on
self report or general practice registers – the large
proportion of patients with type 2 diabetes that is
presumed to be undiagnosed (and could be as high as
50%) [10, 11] can give rise to varying ﬁndings, espe-
cially because this proportion again may vary be-
tween regions or countries. Not only national but
also international literature presents few publications
with detailed data on the highest age categories: these
publications are diﬃcult to compare because of con-
siderable diﬀerences in deﬁnitions and study design,
and they show highly varying prevalence rates [12–
19]. As the prevalence of type 2 diabetes increases
quickly and is estimated to be highest in the eldest age
categories, we consider it important not to ignore this
age category and to present actual data on current
prevalence, incidence and mortality of known dia-
betes in all age groups, including these eldest. These
data could be used to describe temporal trends and
can support health-care planning. Therefore, in the
light of all the above arguments, the aim of this study
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is to present actual data from a large population in
order to be able to estimate current prevalence, inci-
dence and mortality of type 2 diabetes, as known in
or identiﬁed through the normal health-care pro-
cesses, in all age categories in The Netherlands.
Methods
The Zwolle Outpatient Diabetes project Integrating
Available Care (ZODIAC)-study investigates the ef-
fects of a shared-care project for type 2 diabetes. In
this project general practitioners (GPs) receive sup-
port from diabetes specialist nurses for the practical
implementation of the national guidelines with re-
spect to performing the annual control and education
in patients with known diabetes. This working pro-
tocol does not, in any way, aim to inﬂuence in the
actual process of diagnosing diabetes and screening
high-risk populations; so (changes in) prevalence and
incidence are considered comparable with those
found in the normal health-care process. In the pro-
ject, 61 GPs from an eastern part of the country
participate. These are all the GPs of the 8 GP-
working groups covering the project target area. A
GP-working group consists of GPs – with practices in
the same town or city – collaborating mainly with
respect to delivering medical service in out-of-oﬃce
hours. GPs could only participate in the project with
their total working-group, and all groups invited
agreed to participate. This means that among par-
ticipating GPs there are some with a special interest
and others with no special interest in diabetes. In The
Netherlands, virtually each inhabitant is registered
with a GP.
As part of the ZODIAC-study, we collected cross-
sectional data on the general population and all pa-
tients with diabetes, as registered with the 61 GPs, in
three consecutive years: 1998–2000. Lists naming all
patients known with type 2 diabetes, as deﬁned by the
national guidelines of the Dutch College of GPs of
1989 and 1999 (based on the 1985 World Health
Organisation (WHO) and 1997 American Diabetes
Association (ADA) criteria, respectively), were pro-
vided annually by the GPs and checked for each in-
dividual practice by the principal investigator. These
lists were composed combining information on glu-
cose measurements, HbA1c, use of diabetes medica-
tion and special markers for signalling diabetes in the
patient ﬁles. A manual check, consisting of a review
of the complete paper and/or electronic patient ﬁle,
for the validity of the diagnosis, the type of diabetes,
and the date of diagnosis was performed by the
principal investigator of the study for each individual
patient with diabetes in each practice. Patients with
type 1 diabetes, deﬁned by age at diagnosis as
<40 years and requiring insulin within 1 month of
diagnosis, were removed from the lists. The validity
of the diagnosis type 2 diabetes was checked in the
individual patient ﬁles by looking up the glucose
measurements the diagnosis was based upon, and
comparing these measurements with the criteria for
diabetes in the national guideline at the time of di-
agnosis for each patient. Incident cases (newly diag-
nosed cases) were deﬁned as having a diabetes
duration of <1 year at baseline or in the ﬁrst or
second study year. The total general population,
registered with the participating 61 GPs at baseline,
consisted of 155,774 persons. The practices had
computerised patient lists and all supplied the total
number and age- and sex-distribution of the total
general population registered with their practice in
each study year.
To extrapolate our ﬁndings for the Dutch popu-
lation, we used national data on age- and sex-distri-
bution from the Central Bureau for Statistics for each
year corresponding with the study years [20]. To
check the external validity of the data, the age- and
sex-distribution of the study population and national
population were compared. Prevalence rates were
calculated as percentages per 5- and 10-year age
category. The 95% conﬁdence intervals (CI) for dif-
ferences between observed proportions were calcu-
lated for each age category. Incidence rates were
calculated per 10,000 per 5- and 10-year age category.
Standardised mortality ratios (SMRs) were calcula-
ted for patients with known type 2 diabetes, dividing
the observed number of diabetic deaths by the num-
ber of expected deaths in the general population,
using the Dutch 1998 population as the reference
population [20]. Expected numbers were calculated
per 5-year age category.
This study was approved by the Medical Ethics
Committee of the Isala Clinics (formerly Weezen-
landen Hospital).
Statistical analyses were performed using the Sta-
tistical Package for Social Sciences (SPSS, version
8.0.1).
Results
The age and sex distribution of the total general
population studied was marginally diﬀerent from the
national population, mainly in the age categories 20–
29 and 65–69 years (Figure 1). In these categories the
diﬀerence between the proportions of the age cate-
gories from the total study population and the na-
tional population was 2.2 and 0.4%, respectively.
Prevalence
At baseline, 3369 patients known with type 2 diabetes
were identiﬁed in the total population of 155,774
persons. The mean age of the diabetic population was
67.7 years (standard deviation SD: 12.6) overall, and
69.7 (SD: 12.3) vs. 65.1 (SD: 12.3) for women and
men, respectively. Age ranged from 19 to 102 years.
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The overall crude prevalence was 2.16%; the age-
and sex-adjusted prevalence for The Netherlands was
2.21% (95% CI: 2.13–2.28). Prevalence for women
was 2.4 vs. 2.0% in men. The prevalence per age
category is presented in Table 1 and Figures 2 and 3.
The highest prevalence was found in the age category
70–79 for both women and men. After 2 years of
follow-up, the population on the lists of participating
GPs consisted of 156,074 persons; the number of
participating GPs did not change, but the general
population of the practices had grown in the study
period, as in the rest of The Netherlands. Because of
this change, data on age and sex distribution of the
general population of each speciﬁc study year were
used for the age- and sex-adjustment. In this general
population, 4423 patients were known with type 2
diabetes after two follow-up years. Crude prevalence
had increased to 2.83% overall, age- and sex-adjusted
prevalence to 2.94% overall, to 3.1% for women and
to 2.7% for men. For the diabetes population this
meant an increase of 33% (women 30%, men 37%) in
2 years. The age distribution for known type 2 dia-
betes for the male population shifted towards the















































Figure 1. Age and sex distribution of the study population
and national population. The Netherlands –¤–, General
population study area –h–.
Table 1. Prevalence per 5- and 10-year age categories for men and women







(%) Total (N) Total Women Men
Absolute
diﬀerence (%) 95% CI
0–4 0 0.0 0 0.0 0.0 0.0 0.00 0.00–0.00
5–9 0 0.0 0 0.0 0.0 0.0 0.00 0.00–0.00
10–14 0 0.0 0 0.0 0.0 0.0 0.00 0.00–0.00
15–19 1 0.0 1 0.0 0.0 0.0 0.00 )0.03–0.03
20–29 8 0.0 8 0.0 0.0 0.0 0.00 )0.04–0.03
30–39 63 0.3 76 0.3 0.3 0.3 0.05 )0.04–0.14
40–49 249 1.2 314 1.5 1.3 1.6 0.29 0.08–0.50
50–59 587 3.2 778 4.3 3.6 4.9 1.05 0.67–1.43
60–64 370 5.8 480 7.5 7.0 8.1 1.73 0.91–2.56
65–69 477 8.6 576 10.4 10.4 10.4 1.77 0.75–2.79
70–79 1091 10.7 1437 14.0 14.1 13.9 3.35 2.43–4.27
80–89 466 10.7 667 15.3 15.4 15.1 4.59 3.17–6.02
>90 57 8.2 86 12.3 12.6 11.1 4.05 0.81–7.30












































Figure 2. Prevalence of type 2 diabetes at baseline. Total















































Figure 3. Prevalence per 5- and 10-year age category at
baseline and after 2 years. Baseline –¤–, After two follow-
up years –h–.
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patients in The Netherlands in 2000, according to the
prevalence found, is estimated to be 466,000.
Incidence
The number of patients with newly diagnosed type 2
diabetes at baseline and in year 1 and 2 are shown in
Table 2. The overall crude mean annual incidence
was 22.0/10,000 and the age- and sex-adjusted inci-
dence 22.7/10,000 (95% CI: 22.5–22.9). For women
this was 23.1 and for men 22.2/10,000. The highest
incidence for both women and men was found in the
age category 65–69, where it was 87 and 97/10,000
per year, respectively. Based on the incidence found,
the annual number of patients with newly diagnosed
diabetes is estimated to be approximately 36,000 per
year in The Netherlands.
Mortality
From the baseline population (n ¼ 3369), 323 (9.6%)
patients died during the 2-year follow-up period. The
mean age of these patients was 79.3 years (SD: 10.5,
range 38–104 years), for women (54.2%) this was
81.5 and for men 76.8 years. The mortality rate was
47.9/1000 for the diabetic population and 8.8/1000
for the total general population in 1998. The SMR for
the total diabetic population is 1.40, for women 1.41
and for men 1.44, as compared to the general popu-
lation. The relative mortality risks per age category
are shown in Table 3.
Elderly population
In the population aged 70 years and older, prevalence
is higher than in any other age category. Patients
aged 70 years and over account for almost half
(49.5%) of the total type 2 diabetes population. There
is an increase in prevalence with age until the age of
80 at baseline and until the age of 90 after 2 years of
follow-up. After the age of 90, prevalence decreases.
The largest absolute increase in number of patients
with known type 2 diabetes was found in the age
category 70–79; the largest absolute increase in
prevalence was found in the age category 80–89. The
incidence – even though still high between the age of




Our study, which is limited to known type 2 diabetes,
presents actual data from a large population to esti-
mate current prevalence, incidence and mortality in
The Netherlands; our main conclusion is that the
prevalence is considerably higher than described or
estimated up till now. This is the case for both the
overall prevalence [6, 21] and for the prevalence in all
diﬀerent age categories [11, 22–24]. Incident cases
explain a part of the rise in prevalence. The incidence
we found is also higher than what has been published
for The Netherlands up to now, overall as well as for
the diﬀerent age categories [6, 25], except for 30–39
and 80–89 years [4]. From the original population
4.8% died annually. In the elderly population, aged
70 years and over, prevalence is higher than in any
other age category; this patient category accounts for
almost 50% of all type 2 diabetes patients. Incidence
– even though still high between the age of 70–









up year Total 95% CI Women 95% CI Men 95% CI
0–4 0 0 0 0 0–0 0 0–0 0 0–0
5–9 0 0 0 0 0–0 0 0–0 0 0–0
10–14 0 0 0 0 0–0 0 0–0 0 0–0
15–19 0 0 1 0 0–0 1 1–1 0 0–0
20–29 2 1 3 1 1–1 1 1–1 1 1–1
30–39 8 8 5 3 3–3 3 3–3 3 2–3
40–49 19 29 35 13 12–13 13 13–14 12 12–12
50–59 69 88 92 46 45–47 41 40–43 47 46–49
60–64 36 53 48 71 68–74 68 64–72 72 68–76
65–69 42 58 55 91 87–95 87 82–92 97 91–103
70–79 76 103 92 87 84–91 80 76–83 96 91–101
80–89 36 34 31 76 72–80 73 69–78 84 76–91
>90 2 2 2 29 25–33 36 31–41 0 0–0
Total 290 376 364 22.0 21.8–22.2 22.5 22.2–22.7 21.6 21.3–21.8
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89 years – decreases after a peak at the age of 65–69.
The current detailed data on prevalence and inci-
dence of known type 2 diabetes in general, and spe-
ciﬁcally in the elderly, are new for The Netherlands
and can support health-care planning in our ageing
population. The detailed data on the eldest patients
are also important for international comparisons as
data on these speciﬁc age categories are scarcely
available.
Limitations
The main limitation of our study is the lack of
knowledge regarding undiagnosed diabetes. The
number of undiagnosed patients may be as high as
50% [10, 11]. This group of patients explains the
diﬀerence in prevalence data between epidemiological
studies with diﬀerent designs: studies using oral glu-
cose tolerance tests to screen populations detect also
patients with diabetes who were undiagnosed until
that moment, and studies using registers from GPs or
surveys do not. The size of this group of undiagnosed
patients again might vary between regions or coun-
tries, explaining the diﬀerences found between studies
of the same design in diﬀerent locations. Due to the
extra attention of all care providers regarding the
detection of diabetes and the screening of high-risk
populations, the percentage of undiagnosed diabetes
may have decreased in The Netherlands the past
years, as was found in the United States of America
(US) as well [26, 27]. To get an idea of the magnitude
of the uncertainty regarding the percentage of un-
known diabetes, we compared our incidence rates
with those from an epidemiological study performed
earlier elsewhere in The Netherlands, using oral glu-
cose tolerance tests. They found a cumulative inci-
dence of 6.1–6.9% in the population aged 50–75 at
baseline (according to WHO-85 criteria), with a mean
follow-up duration of 6.4 years [28]. Our data show a
mean annual incidence for this age category which is
31–44% lower. This suggests that there may still be a
large group of patients with undiagnosed type 2 dia-
betes in our population, even though this group may
be decreasing.
Another limitation is that the rise in prevalence
may partly be explained by the introduction of the
revised guidelines of the Dutch College of GPs in
1999 [29]. In these guidelines the 1997 ADA criteria
are used for the diagnosis of type 2 diabetes instead of
the 1985 WHO criteria in the guidelines used until
that moment [30]. Given these criteria, the prevalence
of diabetes mellitus among the general Dutch popu-
lation will change only slightly, but the number of
persons to be classiﬁed in a diﬀerent category after
their introduction is considerable: 39% of the ADA
diabetics are not diabetics according to the current
WHO classiﬁcation, while 38% of the WHO diabetics
are not diabetics according to the ADA criteria [31].
The latter group may still be registered as having
diabetes in the GP registers, causing a higher preva-
lence.
Another explanation for the high prevalence of
known type 2 diabetes found in our region, as
compared to other data derived from GP registers,
may be the long-standing attention for diabetes care
in the area studied. Moreover, the increase in pre-
valence may be explained by the extra attention for
diabetes care because of the shared-care project. Part
of the data used for this study was collected within
the scope of this project. On the other hand, over 70
shared-care diabetes initiatives have been described
in The Netherlands: the above eﬀect on prevalence
of known type 2 diabetes may be found in other
places as well [32]. A ﬁnding supporting the above
Table 3. SMRs per 5-year age category




categories Women Men Total Women 95% CI Men 95% CI Total 95% CI
35–39 1 1 0.00 0.00–0.00 26.46 )46.87–99.78 14.20 )25.17–53.58
40–44 1 1 2 8.36 )14.81–31.54 6.13 )10.86–23.11 7.09 )6.81–20.99
45–49 2 0 2 8.77 )8.42–25.96 0.00 0.00–0.00 2.69 )2.58–7.96
50–54 0 2 2 0.00 0.00–0.00 1.51 )1.45–4.47 1.05 )1.00–3.10
55–59 2 9 11 1.32 )1.26–3.90 3.48 0.26–6.70 2.68 0.44–4.92
60–64 5 7 12 1.73 )0.41–3.87 1.50 )0.07–3.06 1.56 0.31–2.81
65–69 7 10 17 1.15 )0.05–2.35 0.97 0.12–1.82 1.02 0.33–1.70
70–74 24 29 53 1.86 0.81–2.91 1.50 0.73–2.27 1.64 1.01–2.26
75–79 29 26 55 1.28 0.62–1.95 1.12 0.51–1.73 1.16 0.73–1.60
80–84 35 34 69 1.24 0.66–1.82 1.76 0.92–2.59 1.40 0.94–1.87
85–89 40 20 60 1.47 0.83–2.12 1.42 0.54–2.30 1.44 0.93–1.96
90–94 17 6 23 1.33 0.44–2.23 1.02 )0.13–2.17 1.25 0.53–1.96
>95 13 3 16 1.43 0.33–2.54 1.93 )1.16–5.01 1.50 0.46–2.53
Total 175 148 323 1.41 1.11–1.70 1.44 1.11–1.76 1.40 1.18–1.61
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theory is that the increase in prevalence is partly
explained by the improvement in GP-registrations
during the follow-up years. Patients who were di-
agnosed, but not yet registered correctly up until
that moment, explained almost 40% of the rise in
prevalence (in the ﬁrst follow-up year 40% and in
the second 38%). This phenomenon was also found
in another Dutch study that showed that it took
10 years of continuous attention for the disease and
its registration before the reservoir of unregistered
patients was empty [33]. In our opinion, after 3 years
of annually composing diabetes lists, combining in-
formation on glucose measurements, HbA1c, use of
diabetes medication, and special markers for signal-
ling diabetes in the patient ﬁles, and after annual
extensively checking the lists manually in each
practice, the proportion of unregistered known pa-
tients with diabetes will be reduced to a minimum.
Moreover, the patients with diabetes we found, are
all true cases of type 2 diabetes: by checking all in-
dividual patient ﬁles, we know that no false positive
cases were included.
Comparison to other national and international studies
Prevalence
As already stated, our main conclusion is that the
prevalence of known type 2 diabetes is higher than
described for The Netherlands up till now for both
the overall prevalence [6, 21] and for the prevalence in
all diﬀerent age categories [11, 22–24]. The most re-
cent prevalence estimate from Baan et al. [6] was 2.7–
3.2% for the population aged >30, whereas we ﬁnd
4.7% for this age category. However, our prevalence
rates of known type 2 diabetes do not yet reach the
prevalence of combined diagnosed and undiagnosed
diabetes, as found in earlier epidemiological studies,
showing that undiagnosed diabetes is still present.
Our prevalence is approximately 75% of the preva-
lence found in Hoorn [11] and in Rotterdam [22]. The
estimated number of 466,000 patients with known
type 2 diabetes in 2000 exceeds all current and future
projections for The Netherlands [6, 7, 9, 23]. Projec-
tions from the nineties regarding the increase in the
next 15–20 years, vary between 20 and 50%. We
found an increase of 33% in 2 years. The overall
prevalence of known type 2 diabetes is higher in
women than in men, as shown in other studies [11,
22], but lower for women aged <64 which was also
shown by Mooy et al. [11] and Han et al. [34].
Prevalence rises sharply in the two follow-up years.
The largest absolute increase in known type 2 dia-
betes is found in the age group 70–79 and not be-
tween 45 and 65 as was predicted [7].
As compared to international prevalence rates we
ﬁnd a higher overall prevalence (2.9%) in The
Netherlands than in Italy (2.5%) and the United
Kingdom (UK) (2.0%) [35, 36], and this also ap-
plies for the diﬀerent age categories in these coun-
tries [37, 38]. In the US, the overall prevalence
among white non-Hispanics is higher in most pub-
lications: for the population aged >20, Harris et al.
[27] found a prevalence of 4.8% and Mokdad et al.
[39] found 5.9%, vs. 3.9% in this age category in
our results.
Incidence
Incident cases explain a part of the rise in prevalence.
The incidence we found is higher than what has been
published up till now for The Netherlands, overall as
well as for the diﬀerent age categories [6, 25], except
for 30–39 and 80–89 years [4].
As compared to international incidence rates we
ﬁnd a higher overall incidence (2.27/1000) than in the
UK (1.63/1000) [36]. Compared to our data, the
numbers found for the US are too divergent to allow
for a valid conclusion [40, 41].
Mortality
From the original population 4.8% died annually.
Baan et al. [5] estimated the number of diabetic deaths
as a percentage of the total number of deaths to be
18.1% for women and 11.9% for men. According to
our results this is lower: 13.1 and 11.4%. This might
be explained by the fact that the estimates from Baan
et al. [5] are based on mortality ratios from the Verona
Study (Italy): these are higher for every age category
than the mortality ratios we observed, especially for
women [35]. In a Dutch study, De Grauw et al. [42]
found a mortality ratio of 1.62 and 1.56 for women
and men, respectively, as compared to 1.41 and 1.44 in
our results. This might be explained by the diﬀerence
in study design: we compared to the total general
population (including patients with diabetes) whereas
they compared to matched cases from the non-dia-
betic population.
As compared to international data, we ﬁnd a
higher mortality rate (47.9/1000) than in the UK
(41.8/1000) [43]. In the US mortality rates for the
population aged >65 years are comparable to ours
[44]. In an international meta-analysis the percentage
of patients dying annualy was found to be lower
(3.8%) than in our results (4.8%) [45].
Elderly
No detailed Dutch data on prevalence in the age
category >90 years were found but up until the age of
90 the prevalence rates of known diabetes we found
are a lot higher than in earlier research, even though
the pattern of an initially increasing prevalence that
decreases in the eldest patients is similar [11, 22].
Compared with the US, we found a higher prevalence
in the eldest age categories (>70 and >75 years for
diﬀerent studies, respectively) [27, 39, 46]. Incidence –
even though high between the age of 70–90 years –
decreases after a peak at the age of 65–69. For women
between 80 and 89 years, we found a lower incidence
than others did: 73/10,000 vs. an estimated 103/
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10,000 by Barendregt et al. [4]. The Dutch Sentinel
Practice Network found a peak between 65 and
79 years [25]. The estimated incidence by others
shows a continuous rise without a peak [4, 6].
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